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MicroRNAs (miRNAs) are small non-coding RNAs involved in post-transcriptional gene
regulation. Recently, growing evidence has shown that miRNAs are taken in by intracellular
exosomes, secreted into circulation, and taken up by other cells. Circulating levels of
several miRNAs are changed in diseases such as cancer, diabetes, and cardiovascular
diseases; therefore, they are suggested to regulate functions of the recipient cells
by modulating protein expression. Circulating miRNAs (c-miRNAs) may also modulate
skeletal muscle function in physiological and pathological conditions. It has been
suggested that acute and chronic exercise transiently or adaptively changes the level
of c-miRNAs, thus post-transcriptionally regulating proteins associated with energy
metabolism, myogenesis, and angiogenesis. Circulating levels of several miRNAs that
are enriched in muscle are altered in muscle disorders and may be involved in their
development and progression. In addition, such c-miRNAs may be useful as biomarkers to
determine various interactions between tissues and also to reflect athletic performance,
physical fatigue, incidence risk, and development of diseases.
Keywords: microRNA, skeletal muscle, circulation, exosome, exercise, muscular disease
INTRODUCTION
MicroRNAs (miRNAs) are small non-coding RNAs of approxi-
mately 19–22 nucleotides in length that regulate gene expression
at the post-transcriptional level through mechanisms such as
translational inhibition or mRNA degradation. DNA encoding
small non-coding RNAs is transcribed by RNA polymerase II,
producing long primary transcripts (pri-miRNAs) that are then
cleaved into 60–70-bp stem-loop precursors (pre-miRNAs) by the
microprocessor, which includes RNase III enzyme Drosha and
DiGeorge syndrome critical region gene 8 (DGCR8) (Figure 1)
(Kim et al., 2009; Winter et al., 2009). The pre-miRNA is sub-
sequently transported from the nucleus to the cytoplasm by
exportin-5 and further cleaved by the Dicer complex into mature
miRNAs (e.g., miRNA duplex). One strand of the mature miR-
NAs is then incorporated into a ribonucleoprotein complex called
the miRNA-induced silencing complex (miRISC) and the other
strand is degraded (Wienholds and Plasterk, 2005). miRISC sup-
presses gene expression through hybridizing, either completely
or partially, to complementary binding sites located in the 3′
untranslated region (UTR) of target mRNAs and degrading the
mRNAmolecules or inhibits their translation in mammalian cells
(Bartel, 2004; Djuranovic et al., 2012; Pasquinelli, 2012).
Biogenesis of miRNA is regulated through several steps. First,
transcriptional regulation modulates the expression of miRNA.
Several genome-wide approaches have revealed transcription fac-
tors associated with miRNA promoters. Transcription factors that
regulate specific miRNAs are often themselves targets of those
miRNAs in positive or negative feedback loops (Martinez et al.,
2008). Conversion from pri-miRNA to pre-miRNA, regulated
by microprocessors, is another rate-limiting step. Microprocessor
activity can be regulated by factors such as p68 and p72 (Gregory
et al., 2004). Thereafter, export of pre-miRNA from the nucleus
to the cytoplasm depends on the activity of exportin 5. Processing
of pre-miRNA to mature miRNA is regulated by Dicer activity. In
addition, the degradation rate of miRNA, e.g., stabilization, plays
an important role in modulating miRNA levels.
Generally, a single miRNA can regulate the expression of over
100 mRNAs and proteins (Ambros, 2004; Bartel, 2004). In fact,
over 60% of protein-coding genes may be regulated by miR-
NAs (Friedman et al., 2009), and much of these miRNAs are
suggested to have a role in a wide range of biological processes
such as development, homeostasis maintenance, and adaptation.
Misexpression of miRNAs results in the onset of diseases such as
immune diseases, cardiovascular diseases (CVDs), neurological
diseases, and cancer (Mendell and Olson, 2012). Several miRNAs
are also suggested to act as modulators of myogenesis, hypertro-
phy, and nutrient metabolism in skeletal muscle. Some of them
mediate muscle adaptations in response to exercise and diet, as
well as muscular pathogenesis. In addition, it has been known that
several miRNAs are secreted from cells into circulation or taken
from circulation into cells (Figure 1). Many researchers studying
areas such as disease, aging, and physical exercise are now focusing
on the association of c-miRNAs with various physiological and
pathological phenotypes.
ROLE OF miRNAs IN MUSCULAR FUNCTION
A tissue-specific miRNA is defined as a mature miRNA that is
expressed in a specific tissue at levels that are >20-fold higher
than the mean levels in all other tissues (Lee et al., 2008).
Recently, there has been increasing evidence regarding the roles
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FIGURE 1 | Hypothetical illustration of relevance between circulating
microRNA and skeletal muscle. Small non-coding RNAs are
transcribed by RNA polymerase II (Pol II)-producing long primary
transcripts (pri-miRNAs), which are then cleaved into stem-loop
pre-miRNAs by the microprocessor, which includes the RNase III
enzyme Drosha and DiGeorge syndrome critical region gene 8 (DGCR8).
The pre-miRNA is subsequently transported from the nucleus to the
cytoplasm by Exportin-5 and further cleaved by the enzyme Dicer into
mature miRNAs. Mature miRNAs are incorporated into RNA-induced
silencing complex (RISC). The RISC acts by hybridizing, either perfectly
or partially, to complementary binding sites located in the 3′
untranslated region (UTR) of target mRNAs and inhibiting translation by
mRNA cleavage or steric hindrance, which leads to various phenotypic
changes. In addition, several miRNAs can be taken into an intracellular
exosome and secreted into circulation. Circulating miRNAs move into
other organs or muscle itself and may regulate their functions.
and regulation of miRNAs in skeletal muscle. miR-1, miR-133,
andmiR-206 are highly enriched in both human andmouse skele-
tal muscle (Sempere et al., 2004). It has been shown that the
expression of miR-1, miR-133a, miR-133b, and miR-206 corre-
sponds to nearly 25% of all miRNA expression in skeletal muscle,
and thus they are often referred to as muscle-specific miRNAs
or myomiRs (McCarthy, 2008). These four miRNAs belong to
the miR-1 family, which can be divided into two groups: miR-
1/206 and miR-133a/b, on the basis of the sequence of the seed
region. Thus, the regulation of these muscle-specific miRNAs as
well as their relationship with muscle functions such as myogen-
esis, hypertrophy, and energy metabolism, has been of particular
interest.
Expression of muscle-specific proteins/miRNAs is regulated
by key myogenic regulatory factors (MRFs), myocyte enhancer
factor 2 (MEF2), serum response factor (SRF), and myocardin-
related transcription factor-A (Chen et al., 2006; Rao et al., 2006;
Rosenberg et al., 2006; Liu et al., 2007; Small et al., 2010).
In addition to downstream MRFs, muscle-specific miRNAs
influence myoblast proliferation and differentiation through
repression of SRF, histone deacetylase 4 (Chen et al., 2006), DNA
polymerase (Kim et al., 2006), and the upstream paired box
protein Pax-7 (Dey et al., 2010). Thus, miRNAs are involved
in myogenesis via their regulatory relationship with MRFs. In
addition, these miRNAs also modulate muscle hypertrophy and
atrophy by acting as repressors of growth factor gene targets,
chaperones, and caspases (Clop et al., 2006; McCarthy et al., 2007;
Xu et al., 2007).
In addition to miR-1, miR-133a/b, and miR-206, other miR-
NAs such asmiR-208, miR-486, andmiR-499 are also abundant in
muscle and have specific functional roles in skeletal muscles. miR-
208b and miR-499 are encoded in introns in the myosin heavy
chain genes MHC7 and MHC7b, respectively, which are enriched
in type I fibers (McCarthy, 2011), by regulating target genes such
as Sry-box 6 (Sox6), thyroid hormone receptor associated protein
1 (Thrap1), and purine-rich element-binding protein and also by
Frontiers in Physiology | Striated Muscle Physiology February 2014 | Volume 5 | Article 39 | 2
Aoi and Sakuma Circulating microRNA and skeletal muscle
repressing β-MHC expression (van Rooij et al., 2009; Bell et al.,
2010; McCarthy, 2011). In addition, another predicted target of
miR-208b and miR-499 is GDF8, which is also known as myo-
statin, a major negative regulator of muscle mass (Drummond
et al., 2009). Phosphatase and tensin homolog (PTEN) and fork-
head box transcription factor O1 A, which serve as negative
components of phosphoinositide-3-kinase (PI3K)/AKT signaling
(Small et al., 2010), are targets of miR-486. Through gain- and
loss-of-function experiments, it was shown that miR-486 modu-
lates PI3K/AKT signaling by directly targeting PTEN, an inhibitor
of PI3K phosphorylation, thereby promoting the phosphoryla-
tion of Akt and the activity of downstream components of the
pathway. Furthermore, miR-181 is upregulated upon myogenic
differentiation, and it targets homeobox AII, a repressor of the
differentiation process, to allow new muscle growth (Naguibneva
et al., 2006). miR-24 is also related to myogenesis via modula-
tion of transforming growth factor β, myogenin, and MEF2 (Sun
et al., 2008). Furthermore, some miRNAs have been suggested to
regulate metabolic modulators. Increased expression of miR-696
in skeletal myocytes leads to negative regulation of the peroxi-
some proliferator-activated receptor gamma, coactivator 1 alpha
(PGC-1α) protein, along with reduced expression of the mRNAs
for its downstream genes (Aoi et al., 2010). miR-23 can also neg-
atively regulate PGC-1α mRNA and protein and its downstream
metabolic proteins in mice skeletal muscle (Safdar et al., 2009).
Each miRNA has many targets, making it difficult to deter-
mine the significance of miRNA changes to various physiological
and pathological conditions. In addition, changes in miRNAs are
often contradictory, suggesting that the effect of the miRNA and
its network of gene targets on muscle phenotypic change is com-
plex, and it is currently unclear whether we can use miRNA levels
as a biomarker for particular phenotypes. Furthermore, miRNA
responses likely vary between species and under different exercise
and diet conditions, as well as sampling conditions.
c-miRNAs AND MUSCLE PATHOLOGY
Recently, growing evidence has shown that some miRNAs exist
in circulation (Figure 1). In 2007, Valadi et al. demonstrated
that miRNAs were taken into intracellular vesicles exosomes,
which are small membranous vesicles derived from the endosome
(Raposo and Stoorvogel, 2013), and released into circulation.
Circulating miRNAs can originate from various types of cells,
including parenchymal cells, blood vessel cells, and blood cells.
Although a detailed mechanism for the secretion of miRNAs from
cells has not yet been established, Kosaka et al. (2010b) reported
that miRNA secretion was regulated by neutral sphingomyeli-
nase 2, a rate limiting enzyme in the biosynthesis of ceramide,
which triggers the secretion of exosomes. Many subsequent stud-
ies have shown the existence of circulating miRNAs (c-miRNAs)
in various human body fluids, including serum, plasma, breast
milk, urine, saliva, and other interstitial fluids (Kosaka et al.,
2010a). In addition to exosomes, other extracellular vesicles such
as microvesicles and apoptotic bodies, and non-vesicle-associated
proteins such as HDL/LDL or RNA-binding proteins such as
Argonaute are known to be involved in the process (Arroyo et al.,
2011; Turchinovich et al., 2011; Vickers et al., 2011). Profiles of c-
miRNAs are changed by conditions such as disease and pregnancy
(Chim et al., 2008), indicating that c-miRNAs can be used as
biomarkers to monitor such conditions (Lawrie et al., 2008). A
unique characteristic of c-miRNAs is that they can circulate in the
blood without degradation by RNases. In addition, c-miRNAs can
be transported from circulation into other cells and can regulate
functions of the recipient cells (Valadi et al., 2007). Thus, miRNAs
are thought to be able to determine various interactions between
tissues and to reflect physiological and pathological states.
Previously, many c-miRNAs have been identified, particularly
in cancer studies. For example, miR-21 is a well-characterized
miRNA that contributes to the development of cancer (Schetter
et al., 2008; Medina et al., 2010). This miRNA has been shown
to regulate several tumor suppressor genes (Meng et al., 2007;
Asangani et al., 2008). Several reports have shown an increased
expression of circulating miR-21 in the serum of patients with
various types of cancer, including diffuse large B-cell lymphoma,
osteosarcoma, colorectal cancer, hepatocellular carcinoma, gas-
tric cancer, prostate cancer, and glioblastoma (Lawrie et al., 2008;
Skog et al., 2008; Yaman Agaoglu et al., 2011; Zhou et al., 2011;
Kanaan et al., 2012; Li et al., 2012; Ouyang et al., 2013); there-
fore, for diagnosis, it may be useful to examine the expression
of circulating miR-21 in the serum of cancer patients. Likewise,
circulating levels of miRNAs such as miR-1 and miR-133, which
are highly expressed in the heart, are increased in CVDs. Because
these miRNAs are more abundant in the serum of patients than
that of normal/healthy subjects, they might be useful as potential
biomarkers for disease. Indeed, c-miRNAs may contribute to the
pathogenesis of disease by regulating protein expression in tar-
get cells (Mitchell et al., 2008; Wang et al., 2009, 2010; Heneghan
et al., 2010). In culture, secreted miRNA is transferred into a
recipient cell, where it exerts its function (Kosaka et al., 2010b).
However, it is unclear how circulatingmiRNAs are associated with
disease onset, development, or recovery.
As mentioned above, several miRNAs act as modulators of
skeletal muscle cell function such as proliferation, differentia-
tion, hypertrophy, and nutrient metabolism (Chen et al., 2006;
Cardinali et al., 2009; McCarthy et al., 2009; Dey et al., 2010).
Indeed, muscle disorders, exercise, immobilization, and intake of
amino acids can change the level of miRNAs in skeletal muscle,
which is suggested to account for phenotypic changes (Eisenberg
et al., 2007; McCarthy et al., 2007; Safdar et al., 2009; Aoi et al.,
2010; Nielsen et al., 2010; Deng et al., 2011; Mizuno et al.,
2011). Although the mechanisms underlying the secretion of
skeletal muscle miRNAs into blood by particular physiological
and pathological conditions remain unclear, many researchers
focus on defining c-miRNA profiles, which may include a pos-
sibility to become useful biomarkers for such conditions and
may be involved in translating muscle phenotypes to whole body
phenotypes, e.g., muscle disorder and exercise-induced health
promotion (Table 1).
Recently, it has been reported, in animal studies, that sev-
eral miRNAs that are highly expressed in muscle can be detected
in plasma and serum, and are changed by muscle disorders.
Mizuno et al. (2011) have shown that the serum levels of miR-1,
miR-133a, andmiR-206 are increased in Duchennemuscular dys-
trophy (DMD) models, dystrophin-deficient muscular dystrophy
mouse (mdx) and X-linked muscular dystrophy dog, compared
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Table 1 | Change of circulating microRNAs in muscular physiological and pathological conditions.
Condition Increase Decrease References
Dystrophy miR-1, miR-133ab, miR-206 Cacchiarelli et al., 2011; Mizuno et al., 2011;
Roberts et al., 2013; Vignier et al., 2013
COPD miR-1, miR-206, miR-499 Donaldson et al., 2013
Rhabdomyosarcoma miR-1, miR-133ab, miR-206 Miyachi et al., 2010
Type 2 diabetes miR-144 Karolina et al., 2011
Acute aerobic exercise miR-1, miR-133ab, miR-21,
miR-126, miR-146a, miR-181a,
miR-208b, miR-221, miR-222
miR-9, miR-23ab, miR-31, miR-486 Baggish et al., 2011; Uhlemann et al., 2012; Aoi
et al., 2013; Banzet et al., 2013; Russell et al.,
2013
Acute resistance exercise miR-149* Sawada et al., 2013
Aerobic exercise training miR-20a miR-486 Baggish et al., 2011; Aoi et al., 2013
High fitness level miR-21, miR-210, miR-222 Bye et al., 2013
COPD, chronic obstructive pulmonary disease.
with normal animals. Although intramuscular proteins such as
creatine kinase, myoglobin, and lactate dehydrogenase are gener-
ally known as classic circulating biomarkers of muscle disorders,
it is lower specificity to determine presence/absence of disease
because its level is easily elevated by physical stress, such as intense
exercise (Vassella et al., 1965; Nicholson et al., 1986). In con-
trast, the levels of these c-miRNAs are much less affected by
physical stress compared with the levels of intramuscular pro-
teins (Mizuno et al., 2011), suggesting that the circulating levels
of these muscle-specific miRNAs may be more useful and reli-
able biomarkers for muscular dystrophy. Thereafter, Roberts et al.
(2013) confirmed that the dystrophy-involved miRNAs (miR-
1, miR-133a, and miR-206) in serum show dynamic patterns
of expression with the progression of muscle pathology in mdx
mice and that these changes of c-miRNAs are significantly cor-
related with the levels of regeneration factors such as myogenin
in muscle tissue, suggesting these c-miRNAs may be used as
biomarkers of muscle turnover (i.e., myofiber degeneration and
regeneration) although this must be experimentally validated.
The upregulation of miR-1, miR-133a, miR-133b, and miR-206
also has been confirmed in human DMD patients compared with
age-matched subjects (Cacchiarelli et al., 2011; Vignier et al.,
2013), which is in agreement with the results from animal mod-
els (Mizuno et al., 2011; Roberts et al., 2013). In addition to
being higher in dystrophic disorders, levels of muscle-specific
miRNAs, including miR-1, miR-206, and miR-499, are higher
in plasma of patients with chronic obstructive pulmonary dis-
ease, who often exhibit reduced muscle fiber size and propor-
tions due to mechanisms such as inflammation-induced protein
catabolism, compared with control subjects (Donaldson et al.,
2013). In addition, serum levels of muscle-specific miRNAs (miR-
1, miR-133a, miR-133b, and miR-206) are significantly higher in
patients with rhabdomyosarcoma tumor than in those with non-
rhabdomyosarcoma tumors (Miyachi et al., 2010). These results
suggest that a change in the level of these c-miRNAs may be
useful as a biomarker for the clinical diagnosis of rhabdomyosar-
coma in the future, for which there is no serum biomarker
currently known. Furthermore, Karolina et al. (2011) found that
the level of circulating miR-144 increased in type 2 diabetic ani-
mals and humans and that this elevation is negatively correlated
with insulin receptor substrate 1 in insulin-responding tissues,
including skeletal muscle. Thus, the elevation of miR-144 in
circulation may be associated with the development of insulin
resistance in skeletal muscle.
c-miRNA AND PHYSICAL EXERCISE
Baggish et al. (2011) were the first to show that exercise affects
the levels of c-miRNAs associated with angiogenesis and inflam-
mation in competitive male rowers: a single bout of exhaus-
tive cycling or rowing training for 90 days elevated miR-20a,
miR-21, miR-146a, miR-221, and miR-222 levels in plasma.
Although the sources of exercise-induced c-miRNAs remain
unclear, a variety of tissue types relevant to exercise (muscles,
vascular endothelium, and plasma-based platelets and leuko-
cytes) can release c-miRNA into the extracellular space, includ-
ing plasma. In addition, positive correlations between the peak
levels of miR-146a and VO2max and between changes in the
ratio of resting miR-20a to VO2max from pre-training to post-
training have been reported (Baggish et al., 2011). Therefore,
changes in c-miRNAs may be fitness biomarkers and physio-
logical mediators of exercise-induced cardiovascular adaptation
although this must be experimentally validated. Recently, Bye
et al. (2013) assessed whether c-miRNAs are associated with
VO2max-level in healthy individuals. They found that miR-21,
miR-210, and miR-222 were higher in the low VO2max-group
than in the control group. There were no correlations between
traditional risk factors for CVD (blood pressure, cholesterol,
smoking habit, or obesity) and miR-21, miR-210, and miR-222;
however, the authors suggested that these miRNAs have a poten-
tial as new, independent biomarkers of fitness level and risk of
future CVD.
Recently, we investigated the effect of acute and chronic exer-
cise on typical muscle-specific miRNAs in serum obtained from
young healthy subjects who were not habituated to a regular exer-
cise regimen. We found that almost all muscle-specific miRNAs
(miR-1, miR-133a, miR-133b, miR-206, miR-208b, and miR-499)
were present at very low levels in serum (Aoi et al., 2013), in
accordance with the results reported by other groups (Baggish
et al., 2011; Mizuno et al., 2011), suggesting their low secre-
tion from muscle cells into circulation in healthy humans. In
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contrast, we reported that a single bout of cycling exercise at
70% VO2max for 60min decreased the circulating levels of the
muscle-specific miRNA miR-486 immediately after the exercise
(Aoi et al., 2013). This decrease in circulating miR-486 was also
found in the resting state following 4 weeks of cycling training
at 3 days per week. In addition, the change ratio of miR-486
due to acute exercise showed a significant negative correlation
with VO2max for each subject. One mechanism to explain the
decrease in circulating miR-486 in response to exercise may be
reduction in secretion of the miRNA from muscle cells. However,
although the half-life of miR-486 is unknown, 60min of exercise
is probably too short a period to cause a decrease in circulating
levels by reducing secretion. Another possibility is that exercise
may accelerate the uptake of circulating miR-486 into certain
recipient cells. Several studies (Valadi et al., 2007; Kosaka et al.,
2010b; Mittelbrunn et al., 2011) have shown through in vitro
experiments that miRNAs contained in exosomes are transfer-
able from outer media into recipient cells, where they affect their
biological functions. Previously, we found that miR-486 levels
tended to increase in skeletal muscle after exercise training in
mice (data not shown); this may partly be caused by uptake
from circulation to muscle cells although we must experimentally
confirm that circulating mi-486 is transferable and functional in
the muscle cells. A major putative target of miR-486 is PTEN,
which is a negative regulator of phosphoinositide-3-kinase/Akt
signaling, a major pathway downstream of the insulin recep-
tor (Small et al., 2010). It is well-known that a single bout
of exercise activates insulin signaling in muscle cells, thus con-
tributing to glucose uptake as an energy substrate of muscle
contraction. miR-486 may conduct glucose uptake via activa-
tion of insulin signaling and suppression of PTEN, which helps
maintain muscle contraction during exercise. Thus, miR-486
regulates insulin-dependent glucose uptake in metabolic tis-
sues such as the skeletal muscle, and this may be associated
with the negative correlation between circulating miR-486 and
VO2max.
In contrast to previous studies showing that most muscle-
specific circulating miRNAs are unchanged by exercise, Banzet
et al. (2013) reported that miR-1, miR-133a, miR-133b, and miR-
208b can be changed depending on the exercise mode. They
show that these miRNAs were not affected by uphill walking
(concentric), but significantly increased during early recovery
of downhill waking (eccentric) (2–6 h) in healthy subjects. The
resulting elevation of muscle-specific miRNAs may be caused by
cellular leakage with muscle damage following eccentric exercise
(muscle-damaging exercise), which was confirmed by Uhlemann
et al. (2012). However, Russell et al. (2013) showed that in
the 3-h period following a single bout of cycling (non-muscle-
damaging exercise), miR-1, miR-133a, miR-133-b, and miR-181a
levels were increased in untrained male subjects. Therefore, low
levels of circulating muscle-specific miRNAs can be also secreted
in response to exercise. Interestingly, they also reported an ele-
vation in the miRNA biogenesis pathway (Drosha, Dicer, and
exportin-5), and a reduction in the levels of muscle myopathy-
related miRNAs (miR-9, miR-23a, miR-23b, and miR-31) by
acute exercise (Russell et al., 2013), which may be associ-
ated with exercise-derived improvement of muscle function. In
addition to endurance exercise, Sawada et al. (2013) investi-
gated the c-miRNA profile that is affected by acute resistance
exercise. Twelve healthy subjects performed a resistance exer-
cise session (bench press and leg press), consisting of five sets
of 10 repetitions at 70% of maximum strength. However, they
could not find any significant changes regarding muscle-specific
miRNA in serum, regardless of muscle-damaging exercise pro-
tocol. Instead, the level of miR-149∗ in serum increased on the
day following resistance exercise, and miR-146a and miR-221 lev-
els decreased 3 days after exercise. However, the significance of
these changes has not been yet been clarified, because there is no
correlation with other circulating parameters related to muscle
building.
Regular exercise can improve skeletal muscle function, includ-
ing nutrient metabolism and muscle strength, along with reduc-
ing the risk of CVD, type 2 diabetes, and cancer. In addition to the
adaptive effects provided by regular exercise, even a single bout
of exercise induces various benefits including metabolic improve-
ment. Although the detailed mechanism remains unknown,
c-miRNAs, as well as other circulating factors, e.g., hormones,
adipokines, and myokines, may be associated with exercise-
induced benefits.
PERSPECTIVES
The amount of research on miRNAs has grown drastically in the
past 10 years, once we understood that non-coding RNA could
affect phenotypes via post-translational regulation. In addition,
in the past 5 years, there was a breakthrough in research when it
was suggested that miRNAs are present in extracellular fluids and
are changed by various pathological and physiological events. In
the field of skeletal muscle research, such circulating miRNAs are
expected to be found to underlie cellularmechanisms and become
biomarkers for athletic performance, physical fatigue, and inci-
dence risk and development of diseases. However, no miRNAs
have been established as such biomarkers for use in the fitness
or clinical fields.
To advance research and translation, we must address a num-
ber of issues. First, the mechanism of miRNA secretion from
supply cells and uptake into recipient cells must be character-
ized. Indeed, the transfer system of some miRNAs has been
reported in culture experiments (Valadi et al., 2007; Kosaka et al.,
2010b; Mittelbrunn et al., 2011), but c-miRNAs altered by mus-
cle disorders and physical exercise have not been described. The
c-miRNA binding proteins in the exosome and other extracel-
lular vesicles have not been identified. In addition, we must
determine how c-miRNAs recognize their receptor cells. Second,
we must develop protocols for quantification of c-miRNA. The
results of preliminary microarray profiles are often different
from those obtained by quantitative PCR (Chen et al., 2009;
Sato et al., 2009), perhaps due to the difficulty in design-
ing specific probes and primers for miRNAs, which are short
and highly similar. It is also important to develop sampling
techniques to reduce hemolysis in normal body fluid (such
as by optimizing needle thickness) and to identify the ideal
fluid sample (e.g., plasma or serum) (McDonald et al., 2011;
Wang et al., 2012). The problem of how to normalize c-
miRNA levels is also important, because it is unclear whether
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an extracellular housekeeping gene can be used for this purpose.
Further research is needed to characterize the detailed mecha-
nisms and physiological and pathological relevance of changes
in c-miRNAs, and must be based on appropriate measurement
protocols.
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